Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

"There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

Image: prostate cancer cells. Credit: Mateus Crespo, Ana Ferreira, Daniel Nava Rodrigues and Johann de Bono Men with faults in the BRCA2 gene have an increased risk of prostate cancer and could ...

Erectile, Ejaculatory Dysfunction More Common in Cardiac Patients In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it. Prostate ...

The UK National Screening Committee has opened a 12-week public consultation on whether and how prostate cancer screening ...

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, ...

Ribbon structure of the BRCA2 protein. Mutations in the BRCA2 gene are linked to increased risk of breast cancer. New work from UC Davis shows how individual BRCA2 proteins work to repair damaged DNA, ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...